1 / 9

SWEDMAF Trial

SWEDMAF Trial. SWEDMAF Trial. Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Carina Blomstrom-Lundqvist. SWEDMAF Trial: Background. AF is present in a majority of patients undergoing mitral-valve surgery and persists in 80% to 90% of patients after surgery.

xyla-cantu
Télécharger la présentation

SWEDMAF Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SWEDMAF Trial SWEDMAF Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Carina Blomstrom-Lundqvist

  2. SWEDMAF Trial: Background • AF is present in a majority of patients undergoing mitral-valve surgery and persists in 80% to 90% of patients after surgery. • The goal of the trial was to evaluate mitral valve surgery with pulmonary vein isolation (PVI) using epicardial cryoablation compared with mitral valve surgery alone among patients with permanent atrial fibrillation (AF) and mitral valve disease. Presented at HRS2006

  3. SWEDMAF Trial: Study Design 65 patients, age 18-80 years, ECG documented AF for at least 3 months, clinical indication for mitral valve surgery Randomized. 22% female, mean age 65 years, mean follow-up 1 year Surgeons were un-blinded to treatment assignment but both the patient and the cardiologists remained blinded Mitral valve surgery alone n=35 Mitral valve surgery with PVI using cryoablation n=30 • Primary Endpoint: Sinus rhythm at 6 months • Secondary Endpoint: Sinus rhythm at 12 months; quality of life at 6 and 12 months Presented at HRS2006

  4. SWEDMAF Trial: Intraoperative ECC Time Intraoperative ECC Time p=0.0015 • Intra-operative ECC time was longer in the mitral valve surgery with cryoablation group than the surgery alone group (146 min vs. 119 min, p=0.0015), driven by the 21 minute cryoablation procedure time. Minutes Presented at HRS 2006

  5. SWEDMAF Trial: Primary Endpoint Primary endpoint of sinus rhythm at 6 months p=0.024 • The primary endpoint of sinus rhythm at 6 months occurred more frequently in the mitral valve surgery with cryoablation group compared with the mitral valve surgery alone group (73% vs. 46%, p=0.024). Presented at HRS 2006

  6. SWEDMAF Trial: Secondary Endpoint Secondary endpoint of Sinus Rhythm at 12 Months p=0.042 • Secondary endpoint of sinus rhythm at 12 monthswas maintained (73% vs. 49%, p=0.042) Presented at HRS 2006

  7. SWEDMAF Trial: Adverse Events • Adverse events were relatively infrequent, with no deaths in the surgery alone group and 2 deaths in the surgery with cryoablation group, one of which was due to cancer and one due to heart failure. • Bleeding requiring re-operation occurred in 1 patient in the surgery alone group and 3 patients in the cryoablation group. Presented at HRS 2006

  8. SWEDMAF Trial: Results • Among patients with permanent atrial fibrillation and mitral valve disease, mitral valve surgery with pulmonary vein isolation using cryoablation was associated with higher rates of sinus rhythm at 6 months compared with mitral valve surgery without cryoablation. Presented at HRS 2006

  9. SWEDMAF Trial: Summary • Surgery with cryoablation restored sinus rhythm and maintained sinus rhythm more so than surgery alone, with few adverse events. • While the present study demonstrated benefit of cryoablation with mitral valve surgery, data from the present trial do not provide information to the effect of cryoablation with coronary bypass surgery. • The long-term benefit of cryoablation drying cardiac surgery for atrial fibrillation suppression remains to be evaluated Presented at HRS 2006

More Related